Valuation
- Market cap
- 69,009,000
- Revenue TTM
- $0
- Net income TTM
- $-49,230,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 457,200
- Avg volume
- 229,820
- Day's range
- $1.36 – $1.48
- Shares out
- 48,258,000
- Stochastic %K
- 82%
- Beta
- 0.50
- Analysts
- Strong Buy
- Price target
- $4.00
Company profile
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmace...
Show more
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 273 8343
- Website
- https://ikenaoncology.com
- Address
- 645 Summer Street, Suite 101, Boston, United States
Latest news
No headlines yet.
